Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza.
about
Amantadine and rimantadine for influenza A in children and the elderlyAmantadine and rimantadine for influenza A in children and the elderlyAmantadine and rimantadine for influenza A in children and the elderlyViral-bacterial interactions-therapeutic implicationsPostviral Complications: Bacterial PneumoniaTime and dose-dependent risk of pneumococcal pneumonia following influenza: a model for within-host interaction between influenza and Streptococcus pneumoniaeIntervention strategies for an influenza pandemic taking into account secondary bacterial infectionsBacterial complications during pandemic influenza infection.Interaction between influenza virus and Streptococcus pneumoniae in severe pneumonia.Antiviral therapy of influenza.Insights into the interaction between influenza virus and pneumococcusExpression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumoniaA broadly neutralizing human monoclonal antibody is effective against H7N9.Dual Acting Neuraminidase Inhibitors Open New Opportunities to Disrupt the Lethal Synergism between Streptococcus pneumoniae and Influenza Virus.Bench-to-bedside review: bacterial pneumonia with influenza - pathogenesis and clinical implications.Oseltamivir PK/PD Modeling and Simulation to Evaluate Treatment Strategies against Influenza-Pneumococcus Coinfection.Preventing and treating secondary bacterial infections with antiviral agentsAdapting global influenza management strategies to address emerging viruses.Increased susceptibility for superinfection with Streptococcus pneumoniae during influenza virus infection is not caused by TLR7-mediated lymphopenia.The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae.Influenza virus infection decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniaeClinical Characteristics of Influenza-Associated Pneumonia of Adults: Clinical Features and Factors Contributing to Severity and Mortality.Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infectionInfluenza promotes pneumococcal growth during coinfection by providing host sialylated substrates as a nutrient source.Increased Survivorship and Altered Cytokine Profile from Treatment of Influenza A H1N1-Infected Mice with Ekybion: A Drug Complex of Natural Extracts and Inorganic CompoundsEfficacy of quinolones against secondary pneumococcal pneumonia after influenza virus infection in miceInfluenza virus primes mice for pneumonia from Staphylococcus aureus.Both influenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a secondary Streptococcus pneumoniae infection.Toll-like receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenzaThe use of antimicrobial agents after diagnosis of viral respiratory tract infections in hospitalized adults: antibiotics or anxiolytics?Influenza virus M2 targets cystic fibrosis transmembrane conductance regulator for lysosomal degradation during viral infectionDeletions in the neuraminidase stalk region of H2N2 and H9N2 avian influenza virus subtypes do not affect postinfluenza secondary bacterial pneumonia.The use of antiviral drugs for influenza: recommended guidelines for practitioners.How influenza's neuraminidase promotes virulence and creates localized lung mucosa immunodeficiency.In vivo and in vitro studies on the roles of neutrophil extracellular traps during secondary pneumococcal pneumonia after primary pulmonary influenza infectionInfection with human metapneumovirus predisposes mice to severe pneumococcal pneumonia.Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza.Influenza virus neuraminidase contributes to secondary bacterial pneumonia.Induction of pro- and anti-inflammatory molecules in a mouse model of pneumococcal pneumonia after influenza.A live-attenuated pneumococcal vaccine elicits CD4+ T-cell dependent class switching and provides serotype independent protection against acute otitis media.
P2860
Q24187883-DA7DA7A8-9D36-48BF-9D63-6B81B9E3EEBFQ24203853-3C23AB11-52F1-41FA-B927-50D4D31013BFQ24242639-4D99DE2E-9017-4C22-BEC1-484C5CDC5732Q26825261-EEE78EF1-D952-40FE-B65D-7E3BBA3F01A7Q29248089-FB6A0F78-FD32-4840-A01D-AC2F8AB46462Q30222430-47E172A9-3325-4767-847A-69994036BAFEQ30227297-6335C4CE-0200-4798-831A-453E93A60381Q30228111-D372B781-B88D-4CD6-9E38-C17126E5CF95Q30228581-D994DF9E-F4E7-4A92-8E03-4CF1E012EFA8Q30350565-C5B85F79-617B-41AE-854C-F7F20AE3A67CQ30355570-63044D01-CBB1-4B3E-AF55-5CFBED62FA6DQ30365855-57AEBE5D-32C6-4ED4-9AC5-496DF3DEABB9Q30378035-E26303D0-B592-4979-BFC8-E23C873697BEQ30386537-89803DDB-5037-4403-8BE5-3CCDF1AA8AE3Q30389010-17BD0883-9770-4C62-90E6-283E4754091CQ30390145-08B0BBAD-75C1-47F3-B95E-A40DAFC719F1Q30401260-8136E60D-E5ED-4FEA-9AE8-CF422E760AC1Q30431093-EAE73BF7-0A58-4F44-901F-19C9B65F586BQ33418589-3BF12D7F-5A0D-47A2-93F9-8EC20985DBF0Q33554796-442757E2-C99A-4881-A3CA-931BB3E550FCQ33766431-C2485151-BD83-4590-9243-9242F4BF6058Q33828481-D6195605-C1A0-48C0-A5FB-205C30D65102Q33867822-44176675-705F-4B29-835F-8B6CF8766ADDQ33896536-BFE89497-4E34-4EC3-8143-60CFBC585D8BQ34222409-2D54A715-B7EF-4BBE-BCAA-7FF4071B9419Q34352075-E8B4145F-D31E-42F1-8B67-797F4BA6B080Q34763964-BCBCF519-8C5D-46A8-BB2A-49193CB9A872Q35220396-89F8DF8A-0802-47FE-910F-EE7DD9CC9CF4Q35557119-D2C79EA2-B1E7-4643-9BE5-95A81D90880AQ35558420-5DCCBA97-589C-4D42-B35D-91AA557E5548Q35774817-AE7B7ADB-73A8-4A64-84C7-0958B5038F3CQ35826775-36BC2161-C9DE-4EB9-BCDF-1206FAA19833Q36171279-E3D49FBB-0BFF-43AF-AD50-A9ACFCCD8C56Q36653273-77AADAAD-29C8-4D4C-8D86-2DD84652F03AQ36655336-69969015-3791-40E1-AE1E-50A7C3C9DEAEQ37051605-760604B4-FCA5-453B-B01D-F73755634EF7Q37203889-17806B7E-9FAA-4C4B-8F45-520DDED8BF3FQ37275790-5B2CE4B9-9DC2-49A4-A634-B544E5F05425Q37330594-47F418E0-D26F-4372-AA7E-571A6955FAD4Q37606439-E0AFE9B7-8C03-415A-A4A1-C1FEE7D948BA
P2860
Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Effect of antiviral treatment ...... ial pneumonia after influenza.
@en
type
label
Effect of antiviral treatment ...... ial pneumonia after influenza.
@en
prefLabel
Effect of antiviral treatment ...... ial pneumonia after influenza.
@en
P356
P1476
Effect of antiviral treatment ...... ial pneumonia after influenza.
@en
P304
P356
10.1086/421525
P407
P577
2004-06-30T00:00:00Z